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Summary:
The ongoing outbreak of Covid-19 presented with a wide variety of
clinical manifestations. Apart from the common respiratory
complications, acute renal impairment and bleeding complications
on full anticoagulation has been also observed in some patients.
Here we report a  67 year old male with COPD and CKD presented
with symptoms of covid-19 and found ground glass opacity on CT
scan and bibasilar opacity on chest X-ray, admitted to the hospital
and he was initially stable after supportive management, discharged
home on antibiotics but readmitted after 4 days with worsening
shortness of breath, hypoxia, tachycardia (A-fib with Rapid
Ventricular Response) and high ESR. He was started on High flow
nasal cannula (HFNC), diltiazem, adenosine and antibiotics
ultimately needed intubation. While he was on antibiotics,
hydroxychloroquine, DVT prophylaxis and statin he developed
septic shock two days after intubation. Next day he had to receive
Continuous Renal Replacement Therapy (CRRT).
He was placed on heparin infusion. With clinical
improvement the patient was extubated to HFNC, but after
one day of extubation he developed bradycardia, hypotension
and gradually became unresponsive. He was given
vasopressors and intubated again. CT scan showed
retroperitoneal hematoma 10 x7 x 12 cm. His heparin was
discontinued and was managed conservatively. With
supportive treatment his clinical condition improved
gradually and was extubated again. CRRT was switched
from CVVH (Continuous Veno -Venous Hemofiltration) to
HD and eventually he was discharged home.
Clinicians should remain watchful at all stages of critical
care management of COVID 19 because timely intervention
and drug adjustment is lifesaving.
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Case:
The patient is a 67 year old male with history of COPD
(heavy smoker) and CKD who presented to the ED on
3/24/20 for evaluation of fever and SOB (shortness of
breath). Pt was found to have transient hypoxia (SpO2
80s on RA) and his CXR showed bibasilar opacities. CT
imaging showed GGO (ground-glass opacity). Initial
WBC 3.8, PCT 0.80. An RVP (Respiratory Viral panel)
was negative. He was tested for COVID-19 earlier as an
outpatient on 03/24/20. He was given a dose of
ceftriaxone and azithromycin, and subsequently
admitted. His hospital stay was short and uneventful—
he was discharged home on 3/25/20 and prescribed
Amoxicillin/clavulanate potassium for 5 days. He
presented to the ED again on 3/29/20 for worsening
SOB since discharge. Upon initial presentation he was
tachycardic and hypoxic at 89%, he was commenced on
HFNC (High-flow nasal cannula oxygen). The monitor
showed apparent a-fib w/ RVR(Rapid ventricular
response) he did not respond to a 20mg diltiazem bolus.
He was subsequently given adenosine, a second
diltiazem bolus, started on a diltiazem drip, and re-
admitted to the PCU. ESR was initially 92. Upon
admission, he was started on both azithromycin and
hydroxychloroquine given his worsening COVID
pneumonia. Piperacillin/tazobactam was also initiated
in case of a secondary bacterial infection. Shortly after
admission on 3/30/20, he was showing increased
respiratory distress requiring HFNC at 50L w/ FiO2 50%
and ultimately ICU admission and intubation. On 3/30/
20 shortly after intubation he was heavily sedated,
proned, and paralyzed in accordance with ARDS
protocol. He was started on DVT prophylaxis and a
statin on 4/30/20 as well. On 4/2/20 he experienced septic
shock requiring norepinephrine and vasopressin. Pt’s
renal function continued to decline requiring CCRT
(Continuous renal replacement therapy) initiation on 4/
4/20 with Cr 4.85. On 4/5/20, the patient was switched to
a heparin drip and on 4/6/20 the statin was discontinued
because of abnormal LFTs. On 4/8/20, he was given an
extra 100mg of furosemide to facilitate SBT. He was
subsequently extubated to HFNC. On 04/10/20 he
experienced an episode of bradycardia, hypotension,
and unresponsiveness lasting approximately 10-15
minutes. Given his decompensation, shock on
vasopressors, and current condition he was re intubated.
CT scan showed spontaneous retroperitoneal hematoma
10x7x12cm requiring 3 PRBC given his Hb was under 7.
CT imaging of the chest was remarkable for ground glass
opacities throughout and a right pneumothorax for
which chest tube was placed. His heparin drip was also
discontinued on 4/10 given his spontaneous RP bleed.
Echocardiography throughout his ICU stay remained
consistent with preserved LV function. On 4/10 blood
cultures were obtained and he was started empirically
on vancomycin and cefepime for shock and leukocytosis
with WBC 33. A repeat COVID swab on 4/11/20 was
positive and prednisone was switched to
Dexamethasone. He was extubated on 4/14 and switched
from CVVH (Continuous Veno-Venous hemofiltration)
to HD. He was eventually weaned to 2L/min NC. On 4/
16/20 hemodialysis was discontinued, and discharged
home on 4/26/20. Medications administered during his
stay include prednisone, azithromycin,
hydroxychloroquine , vancomycin , cefepime ,
enoxaparin, heparin and Dexamethasone . Of note, the
patient was not treated with Tocilizumab.
Discussion:
Coronaviruses are a large family of viruses that can
infect both humans and animals. The first coronavirus
was found in chickens in the 1930s. Human
coronaviruses were first identified in the mid 60’s. To
date, seven coronaviruses can cause disease in humans.
SARS-CoV-2 is one of seven types of coronavirus,
including the ones that cause severe diseases like
Middle East respiratory syndrome (MERS) and sudden
acute respiratory syndrome (SARS).  COVID-19 has been
declared a public health emergency on January 30th and
pandemic on March 11th by the World Health
Organization.
The complete clinical picture of COVID-19 is not fully
known. Reported cases have ranged from the
asymptomatic cases to the very severe illness (ARDS,
heart failure, renal failure, liver damage, shock and
multiorgan failure) resulting in death. Common signs of
COVID-19 infection are like common cold that includes
respiratory symptoms such as dry cough, sore throat,
fever, breathing difficulties. In addition to respiratory
failure, patients with moderate to severe illness are also
likely to have coagulopathy and may predict mortality.
As it is associated with high thrombotic complications
which can lead to MI,stroke and microangiopathy ,it is
advisable and most protocols use prophylactic
anticoagulation for all COVID-19 patients and full
anticoagulation for certain critical ICU patients with high
inflammatory markers.(LDH, D-dimer, ferritin, CRP etc).
In a study by Tang et al from Wuhan, 71% of non-
survivors from COVID-19 infection met the ISTH criteria
for DIC compared to 0.4% of survivors (1).  Autopsy
reports showed elements of SARS COV- 2, the virus
causing COVID- 19, in cells lining these small blood
vessels in the lungs, kidney and gut along with macro
and micro thrombi2,5. It is still unclear about the
mechanism involved in thrombosis but excessive
inflammation, endothelial dysfunction with high levels
of VWF, and coagulation Factor Viii ,  platelet activation,
stasis and presence of lupus anticoagulant could play a
role in developing hypercoagulable state in covid-19
patients. SARS-COV infection overwhelms the normally
protective profibrinolytic pathway, including
plasminogen activator 13. It was found that upregulation
of fibrinogen synthesis by the liver is stimulated by IL-
6 (4) and was present in almost all patients responsible
for activation of blood coagulation with progressive D-Retroperitoneal bleed.
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dimer elevation. It is assuming that there is bi-directional
synergistic relationship between DIC and cytokine
storm. Studies have found that patients with D-dimer
>1000 during admission are 20 times more likely to die
than patients with lower D-dimer values6. The
involvement of consumption of coagulation factors and
platelets resulting in thrombocytopenia and hypo
coagulant state. Though the bleeding risk is very little.
According to the MOUNT SINAI, NY hospital records
bleeding rate is around 3% in patient on anticoagulation
compare with 2% in patient without anticoagulation but
slightly higher (7.5%) who were intubated7.  Our patient
who was intubated 10 days before and extubated 2 days
before developing retroperitoneal bleed leading to shock
and reintubation. He was initially on DVT prophylaxis
and later on full anticoagulation.
Management can be challenging. In a retrospective
series of 2773 individuals hospitalized with COVID-19,
in whom 786 (28 percent) received systemic
anticoagulation, anticoagulation was associated with
improved in-hospital survival in intubated patients (71
percent, versus 37 percent for those who were not
anticoagulated8. DVT prophylaxis should be initiated
for all hospitalized patients with LMWH unless the risk
of bleeding is judged to exceed the risk of thrombosis
along with mechanical thromboprophylaxis. Choice of
anticoagulant and dose adjustment should be used per
institutional guidance and renal status. Unless
contraindicated  full anticoagulant therapy is
recommended in suspected (sudden deterioration in
respiratory status or otherwise unexplained respiratory
failure or physical findings consistent with thrombosis),
confirmed VTE (venous thromboembolism), recurrent
clotting of intravascular access devices (arterial lines,
central venous catheters) despite prophylactic
anticoagulation and high risk patient (critically ill patient,
markedly elevated inflammatory markers, multi organ
failure, D-dimer >3000 ng/ml or Fibrinogen >8 g/L). A
https://marlin-prod.literatumonline.com/cms/attachment/5ddb9506-2f35-474c-8b09-a62807e9621d/gr1.jpg
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prospective cohort study showed about 96% receiving
CRRT ( Continuous Renal Replacement Therapy)
experienced circuit clotting 9. Parenteral anticoagulant
especially SC enoxaparin is preferred agent. But for a
patient with a history of heparin induced
thrombocytopenia it may be reasonable to use
fondaparinux. It is also reasonable to consider post
discharge extended thromboprophylaxis (30-90 days)
with DOAC (Direct-Acting Oral anticoagulant).10,11. The
existing evidence on thrombotic complications and
management has been based on observational, non RCT,
small, retrospective analyses. Currently few randomized,
open labelled, multicenter clinical trials are underway to
find the detail associations and management.
Our patient also developed AKI (Cr.4.85) 4 days after
intubation needed CRRT (Continuous Renal
Replacement Therapy). AKI is increasingly recognized
in hospitalized COVID 19 patient. Recent studies have
found that in a large cohort of hospitalized patients at
both tertiary care & community hospitals, that the rates
of AKI were much higher than previously reported in
literatures. Studies have found that 36.6% COVID-19
patients developed AKI during hospitalization12. They
have found that AKI occurred in close temporal proximity
to the time of intubation and mechanical ventilation.
Among ventilated patients the rate of AKI was 89.7%,
compared to 21.7% among other patients, 65.5% of
patients on ventilators developed stage II and stage III
AKI compared to 6.7% of non-ventilated patients, and
almost all of the patients requiring RRT were on ventilator
support (276/285) that is 96.8% 12. Another study
showed around 20% of patients admitted to an intensive
care unit (ICU) with COVID-19 require renal replacement
therapy (RRT) at a median of 15 days from illness
onset13. The cause of kidney involvement in COVID-19
is likely to be multifactorial, and predisposing factors
(eg, sepsis, hypovolemia, rhabdomyolysis, macrophage
activation syndrome, micro thrombi and nephrotoxins)
as important contributors. Another potential mechanism





Management of AKI is mainly supportive. COVID-19
patients admitted in ICU with AKI have a very high
tendency of having respiratory failure & sometimes it’s
difficult to differentiate whether it is due to volume
overload or from pneumonia. Respiratory failure may be
the main cause for initiation of RRT (Renal Replacement
therapy) in these patients. Other indications for RRT
are uremic menifestations or severe hyperkalemia14. The
continous Renal Replacement Therapy (CRRT) or
Intermittent Hemodialysis (IHD) are the usual methods
for RRT. But convection based dialysis
(CVVH,CVVHDF) which has the theoretical benefit of
cytokines removal is the better choice for renal
replacement therapy than conventional hemodialysis
which is diffusion based therapy.Sustained Low Efficacy
Dialysis (SLED) as a renal replacement modality has
been increasingly used in crticially ill patients in
developing country15. SLED uses standard machines,
and lower dialysate and blood-flow rates over a longer
time period. When any component of inpatient dialysis
resources is low, urgent start peritoneal dialysis (PD)
for AKI  can be considered16 as an exception.It has
been used in  few hospitals in new york when they ran
out of CRRT( Continuous Renal Replacement therapy)
machines,due to high volume of critically ill patients on
Renal Replacement Therapy. Outcome data are limited,
but acute PD appears to be as effective as other forms
of RRT in the setting of AKI when CRRT is not readily
available17.
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